Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $7.6M in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mack David Henry | President and CEO | Oct 27 '25 | Option Exercise | $1.37 | 220,643 | $302,281 | 451,109 | Oct 29 04:11 PM |
| Orbimed Advisors Llc | 10% Owner |
Company profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Oct 23 '25 |
| Sale |
| $1.52 |
| 1,000,000 |
| $1,520,000 |
| 4,975,291 |
| Oct 27 05:19 PM |
| Orbimed Private Investments V, | Shareholder | Oct 23 '25 | Proposed Sale | $1.52 | 1,000,000 | $1,520,000 | — | Oct 23 06:39 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.